The Fusion Biopsy Market is moving toward more precise, image-guided, and data-driven diagnostic procedures. The market reached approximately USD 0.85 billion in 2024 and is forecast to increase to USD 0.92 billion in 2025 and USD 1.91 billion by 2035, representing a 7.65% CAGR from 2025 to 2035.

Growing cancer prevalence, particularly prostate cancer, is creating demand for improved biopsy techniques. The integration of MRI with ultrasound guidance is helping clinicians target lesions more precisely, while advances in imaging and automation are supporting more efficient procedures. These developments are complemented by increasing patient and provider interest in minimally invasive approaches.

The market structure reflects the growing importance of molecular information in diagnosis and treatment planning. DNA is the largest tech-target segment, while RNA is gaining momentum. Multi-gene Panels lead among products, and Companion Diagnostics are expanding alongside personalized medicine and targeted therapies. Oncology remains the largest application area, reinforcing the importance of fusion biopsy in cancer diagnostics.

North America leads the regional landscape with approximately 45% of global share, followed by Europe at about 30%. Asia-Pacific accounts for around 20% and is witnessing rapid growth due to rising healthcare expenditure, increasing cancer incidence, and broader adoption of minimally invasive technologies.

The future of the market will likely be shaped by AI-enabled imaging, NGS and PCR advances, companion diagnostics, and integrated digital workflows. Companies that develop accurate, efficient, and easier-to-use biopsy technologies can find opportunities as healthcare systems focus on earlier diagnosis, precision medicine, and improved patient outcomes.